• Organizations: BioTissue
Leadership update: ImprimisRx gets new CEO, BioTissue forms MAB
Business

Leadership update: ImprimisRx gets new CEO, BioTissue forms MAB

Leadership changes are underway in the eyecare space—and we’ve got the latest.
Study: BioTissue's CAM improves recovery following corneal CXL
Research

Study: BioTissue's CAM improves recovery following corneal CXL

Research from AAO supports BioTissue’s Prokera as an FDA-cleared therapeutic device for use following epi-off CXL among keratoconus patients.
BioTissue launches CAM360 AmnioGraft regenerative therapy
Products

BioTissue launches CAM360 AmnioGraft regenerative therapy

New hydrated cryopreserved amniotic membrane features anti-inflammatory, scarring, and angiogenic properties for dry eye and ocular surface conditions.
Study reexamines sutureless CAM for DED with short-term treatment
Products

Study reexamines sutureless CAM for DED with short-term treatment

AAOPT poster presentation evaluating 2-day outcomes indicates potential for a more efficient treatment in the future.
Long-term study supports TissueTuck technique following pterygium surgery
Research

Long-term study supports TissueTuck technique following pterygium surgery

Seven-year study assessed use of technique with BioTissue’s AmnioGraft cryopreserved amniotic membrane.